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ABSTRACT
Objectives: To review systematically the evidence of
age-related macular degeneration (AMD) affecting real-
world visual ability and quality of life (QoL). To explore
trends in specific topics within this body of the
literature.
Design: Systematic review.
Methods: A systematic literature search was carried out
using MEDLINE, EMBASE, CINAHL, PsycINFO,
PsychARTICLES and Health and Psychosocial
Instruments for articles published up to January 2015 for
studies including people diagnosed with AMD, assessing
real-world visual ability or QoL as an outcome. Two
researchers screened studies for eligibility. Details of
eligible studies including study design, characteristics of
study population and outcomes measured were recorded
in a data extraction table. All included studies underwent
quality appraisal using the Mixed Methods Appraisal Tool
2011 Version (MMAT).
Results: From 5284 studies, 123 were eligible for
inclusion. A range of approaches were identified,
including performance-based methods, quantitative and
qualitative patient-reported outcome measures (PROMs).
AMD negatively affects tasks including mobility, face
recognition, perception of scenes, computer use, meal
preparation, shopping, cleaning, watching TV, reading,
driving and, in some cases, self-care. There is evidence
for higher rates of depression among people with AMD
than among community dwelling elderly. A number of
adaptation strategies have been associated with AMD of
varying duration. Much of the research fails to report the
type of AMD studied (59% of included studies) or the
duration of disease in participants (74%). Of those that
do report type studied, the breakdown is as follows: wet
AMD 20%, dry AMD 4% and both types 17%.
Conclusions: There are many publications highlighting
the negative effects of AMD in various domains of life.
Future research should focus on delivering some of this
research knowledge into patient management and clinical
trials and differentiating between the types of AMD.
INTRODUCTION
Age-related macular degeneration (AMD) is
a highly prevalent condition which causes
loss of central vision.1 It is the most common
cause of blindness in developed countries
and is labelled a ‘priority eye disease’ by the
WHO.2 In the UK, an incidence of 71 000
new cases of late AMD per year has been esti-
mated.3 Incidence and prevalence are set to
rise as the population ages.4
AMD can be divided into early and late
stages. The early stage, also referred to as
age-related maculopathy (ARM), is charac-
terised by yellow/white deposits (drusen)
beneath the retinal pigment epithelium, and
areas of hyperpigmentation or hypopigmen-
tation.5 6 Later stages may take one of two
forms: neovascular (wet or exudative) AMD
(nAMD), characterised by growth of new
blood vessels beneath the retina with a ten-
dency to leak, causing sudden vision loss, or
geographic atrophy (GA, dry AMD), charac-
terised by sharply demarcated areas of hypo-
pigmentation in which choroidal blood
vessels are more visible than in surrounding
areas, causing more insidious vision loss.5 7
Quality of life (QoL) is a subjective
measure8 9 inﬂuenced by factors including
expectations, relationships,10 routine,11
health and disability.12 QoL is often used
interchangeably with health status, functional
status and health-related quality of life,13 14
although there are subtle differences
Strengths and limitations of this study
▪ This is the first systematic review to include
patient-reported and performance-based
outcome measures in this field.
▪ The most recent systematic reviews in this field
were published almost 10 years ago.
▪ Studies about the effect of age-related macular
degeneration (AMD) on reading were not
included as this is a topic that is already well
reported on.
▪ A large proportion of included studies did not
report type of AMD investigated or duration of
AMD.
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between each of these15 (see table 1). For the purpose
of this article, we use QoL to encompass these slightly
different terms.
QoL is often measured using patient-reported
outcome measures (PROMs), normally via a question-
naire.16 17 This allows ‘a better understanding of the
relationship between the pathophysiology of eye disease
and patient-reported functioning’.18 Performance-based
measures are another type of tool for assessing func-
tional ability or disability. Results from PROMs and
performance-based measures may differ, but this review
will consider both.19–21
As AMD incidence increases, it is important to under-
stand how it affects visual function and QoL. Previous
large-scale systematic reviews, the most recent published
a decade ago,22 23 concentrate on PROMs and do not
describe real-world performance-based measures. More
recent systematic reviews24–28 are much smaller scale,
concentrating on only one aspect of patients’ experi-
ences with AMD, and again, do not consider
performance-based measures. Progress in this ﬁeld
could be an important step towards designing appropri-
ate strategies for monitoring disease progression,
rehabilitation, justiﬁcation of new treatments and design-
ing more meaningful outcomes for clinical trials.
This systematic review investigates the effect of AMD
on visual disability and QoL and explores trends in spe-
ciﬁc topics within this body of literature.
METHODS
A search of the electronic databases MEDLINE,
EMBASE, CINAHL, PsycINFO, PsychARTICLES and
Health and Psychosocial Instruments was undertaken
using keywords relating to AMD, QoL and real-world
visual disability (see online supplementary appendix 1
for a detailed breakdown of search terms).
Retrospective and prospective reference list searches
were conducted for studies meeting eligibility criteria
and relevant reviews. Eligible studies involved people
diagnosed with AMD, considered an aspect of real-world
visual ability or QoL as an outcome, were available in
English and involved human participants only. Studies
were excluded if they only considered standard clinical
measures of visual function. They were also excluded if
outcomes were a result of an intervention or treatment
(including clinical trials) or if an abstract only was pub-
lished (conference proceedings). Review articles were
excluded. Two authors (DJT and AEH) screened studies
to assess eligibility. In the case of disagreements unre-
solved through discussion, a third author (DPC) was
consulted. Owing to the extensive body of literature and
existing reviews29 30 concerning the impact of AMD on
reading, studies concerning this were excluded.
Relevant information (including study design, study
population characteristics and outcomes measured)
from eligible papers was entered into a data extraction
table.
Quality appraisal was conducted using the Mixed
Methods Appraisal Tool 2011 Version (MMAT).31 This is
a recently developed but increasingly recognised tool,
with over 90 citations in the literature, including a
number of high-quality systematic reviews.32–34 This tool
was chosen for this study because it facilitates methodo-
logical appraisal of quantitative, qualitative and mixed
methods studies. Scores are based on meeting criteria,
which differ according to study type. For each criterion
met, a score of 1 is given, up to a possible total of 4 for
each study. Criteria which are not met, or those for which
information is not given in the study, a score of 0 is given.
Full details of grading criteria are shown in table 2.
RESULTS
The search was conducted on 6 January 2015 yielding
5712 results. An additional 15 studies were identiﬁed for
inclusion from reference lists of relevant primary studies
and reviews. Reviewers were in agreement for 5045/5269
(95.7%) of records. Discrepancies were resolved as
described previously. A total of 123 studies were selected
for inclusion. Online supplementary appendix 2 sum-
marises the characteristics and outcomes of these studies.
Many studies were excluded at the record screening stage.
The main reasons for this were that they did not report
outcomes relating to QoL or real-world visual ability or did
not include participants with AMD. Details of assessment
of articles for eligibility along with reasons for excluding
full-text articles are shown in ﬁgure 1.
All 123 included studies underwent methodological
quality appraisal using the Mixed Methods Appraisal
Table 1 Definitions of selected terms related to quality of life (adapted from Patrick et al15)
Term Definition
Functional status An individual’s effective ability to perform valued roles, tasks or activities (eg, going to work,
playing sports or housework).
Health-related quality of life
(HRQoL)
Personal health status. HRQoL usually refers to aspects of our lives that are dominated or
significantly influenced by our mental or physical well-being.
Quality of life (QoL) An evaluation of all aspects of our lives, including, for example, where we live, how we live
and how we play, encompassing life factors such as family circumstances, finances, housing
and job satisfaction.
Well-being Subjective bodily and emotional states; how an individual feels; a state of mind distinct from
functioning that pertains to behaviours and activities.
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Tool 2011 Version (MMAT).31 Eleven studies (9%) had
a score of 2, 33 (27%) scored 3 and the remaining 79
(64%) had a score of 4. Most frequent sources of bias
were related to groups not being comparable and
differences between groups not being accounted for, fol-
lowed by issues regarding recruitment and sample size.
Online supplementary appendix 3 shows details of
quality appraisal for all included studies.
Table 2 MMAT grading criteria (adapted from Pace et al31)
Types of mixed methods study
components or primary studies Methodological quality criteria
(See tutorial for definitions and examples)
Screening questions (for all types) Are there clear qualitative and quantitative research questions (or objectives),
or a clear mixed methods question (or objective)?
Do the collected data allow address the research question (objective)? Eg.
Consider whether the follow-up period is long enough for the outcome to occur
(for longitudinal studies or study components).
Further appraisal may not be feasible or appropriate when the answer is ‘No’
or ‘Can’t tell’ to one or both screening questions
1. Qualitative 1.1 Are the sources of qualitative data (archives/documents/informants/
observations) relevant to address the research question (objective)?
1.2 Is the process for analysing qualitative data relevant to address the
research question (objective)?
1.3 I appropriate consideration given to how findings relate to the context, eg
the setting, in which the data were collected?
1.4 Is appropriate consideration given to how findings relate to researchers’
influence, eg through their interactions with participants?
2. Quantitative randomised control (trials) 2.1 Is there a clear description of the randomisation (or an appropriate
sequence generation)?
2.2 Is there a clear description of the allocation concealment (or blinding where
applicable)?
2.3 Are there complete outcome data?
2.4 Is there low withdrawal/drop-out (below 20%)?
3. Quantitative non-randomised 3.1 Are participants (organisations) recruited in a way that minimises selection
bias?
3.2 Are measurements appropriate (clear origin, or validity known, or standard
instrument; and absence of contamination between groups when appropriate)
regarding the exposure/intervention and outcomes?
3.3 In the groups being compared (exposed vs non-exposed; with intervention
vs without; cases vs controls), are the participants comparable, or do
researchers take into account (control for) the difference between these
groups?
3.4 Are there complete outcome data (80% or above), and, when applicable,
an acceptable response rate (60% or above), or an acceptable follow-up rate
for cohort studies (depending on the duration of follow-up)?
4. Quantitative descriptive 4.1 Is the sampling strategy relevant to address the quantitative research
question (quantitative aspect of the mixed methods question)?
4.2 Is the sample representative of the population understudy?
4.3 Are measurements appropriate (clear origin, or validity known, or standard
instrument)?
4.4 Is there an acceptable response rate (60% or above)?
5. Mixed methods 5.1 Is the mixed methods research design relevant to address the qualitative
and quantitative research questions (or objectives), or the qualitative and
quantitative aspects of the mixed methods question (or objective)?
5.2 Is the integration of qualitative and quantitative data (or results) relevant to
address the research question (objective)?
5.3 Is appropriate consideration given to the limitations associated with this
integration, eg the divergence of qualitative and quantitative data (or results) in
a triangulation design?
Criteria for the qualitative component (1.1 to 1.4), and appropriate criteria for
the quantitative component (2.1 to 2.4, or 3.1 to 3.4, or 4.1 to 4.4), must be
also applied).
MMAT, Mixed Methods Appraisal Tool.
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Below is a short description of the main ﬁndings of
studies included in the systematic review. For further
details of the studies, including experimental design
and sample sizes, see online supplementary appendix 2.
The overview of the study ﬁndings is organised
according to the outcome main dimension. Figure 2
shows the wide range of domains reported by studies
included in this review, the most frequent of which are
mobility (22% of studies) and patient-reported visual
function (17%).
Figure 1 Study selection process.
Figure 2 Domains of QoL and real-world visual ability covered by included studies.
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Performance-based studies
Mobility
Twenty-one studies, including 1131 people with AMD,
investigating the effect of AMD on mobility performance
were identiﬁed. The majority of these (n=14) were case–
control studies, followed by cross-sectional studies (n=5),
along with one cohort study and one longitudinal study.
Basic mobility
Individuals with AMD have been found to travel less and
be less likely to drive than those with other eye dis-
eases.35 They are reported to have poorer balance and
postural stability than non-AMD participants under a
range of conditions.36–38 Binocular central scotoma size
was a predictor of mobility performance in an obstacle
course for people with AMD.39
Road crossing
People with AMD were equally able to detect trafﬁc gaps
when crossing roads, but with a longer delay, reducing
safety margins compared with fully sighted controls and
those with peripheral vision loss.40 People with AMD
ﬁxated primarily on vehicles rather than trafﬁc lights
while waiting to cross,41 and they have been shown to
make fewer head turns shortly before road crossing, pre-
venting up-to-date road status information being gath-
ered.42 Overall, however, people with AMD were similar
to age-related controls in accuracy and precision of their
road crossing decisions.43
Travel patterns
A uniquely designed case–control study investigated
travel patterns using a cellular tracking device.44 Among
65 participants with AMD, average excursion distance
and span of travel reduced with visual acuity (VA) loss.
Driving skills
One case–control study45 compared detection of trafﬁc
signals in four small groups of volunteers: young and
elderly visually healthy, ARM (n=8, with depressed VA,
fundus changes such as drusen and pigmentary changes,
some central ﬁeld defects and colour vision defects) and
preARM (n=10, deﬁned as normal VA with macular
drusen and/or pigment changes). ARM patients had
slower reaction times. Interestingly, the preARM group
had results outside the limits set by controls, implying that
real-world tasks may be affected before clinically measured
function. Another case–control study46 showed 10 AMD
patients to perform worse than controls on an interactive
driving simulator and an on-road driving test.
Effect of lighting conditions
Six studies assessed mobility under different lighting con-
ditions.47–52 People with AMD walked slowly and cautiously
during light and dark adaptation, while fully sighted
people only behaved in this way during dark adaptation,
indicating that those with healthy vision respond during
dark adaptation as though their vision were impaired.48
People with AMD walk more cautiously, make more gait
modiﬁcations while walking on altered surfaces47 and have
difﬁculty stepping on low contrast targets in dim light and
during dark adaptation.49 AMD affects navigating paths
under low lighting51 and curb navigation particularly
during dim lighting and dark adaptation.50 AMD patients
performed worse on an obstacle course in dim lighting
compared to well-lit conditions.52
Falls and miscellaneous
Two cross-sectional studies found that individuals with
AMD have greater falls risk than those without53 and
that fear of falling results in activity limitation.54 One
case–control study55 used eye tracking and audio feed-
back while participants watched video simulations of
walking through a building: AMD volunteers made more
comments and more ﬁxations than controls.
Faces
Five studies (four case–control and one cross-sectional)
including 171 people with AMD, investigating the effect
of AMD on viewing faces were identiﬁed.
These studies cover a range of outcomes including
familiar face recognition, facial expression discrimin-
ation and eye movements while viewing an image of a
face in people with AMD.56–60 AMD patients performed
better at detecting whether a face had an expression or
not than on categorising the expression.57 In one case–
control study,56 only 26% of a group of 100 AMD
patients correctly identiﬁed the facial expression on all
four photographs shown. Familiar face recognition and
facial expression detection performance has been esti-
mated to worsen with reduced luminance.58 One study
reported signiﬁcant differences in eye movements made
by nine people with AMD compared to nine controls.59
Another indicated perceived disability in face recogni-
tion to not correlate with actual face recognition
performance.60
Scene viewing
Nine studies investigating the effect of AMD on scene
viewing were identiﬁed. These included a total of 176
participants with AMD. These were all case–control
studies.
People with AMD are reported to recognise isolated
objects better than objects in scenes, coloured images
better than achromatic images,61 recognise an object in
a scene more easily when enhanced with a border62 and
when placed on a related compared to an unrelated
background.63 AMD has been shown to affect processing
of high-spatial frequency scenes.64 Moreover, images
have been shown to be more recognisable for AMD
patients at lower spatial frequency bandwidths if the
background is darkened.65 One study asking participants
whether or not a real-world target was present in a scene
at varying levels of contrast found task success to be
strongly related to contrast level.66
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People with AMD have been reported to categorise
scenes as natural versus urban faster and more accur-
ately than indoor versus outdoor, while no differences
were found between these conditions for visually healthy
people.67 In another study, participants undertook a
natural versus urban scene categorisation task in which
images were randomly presented in one of ﬁve locations
on the computer screen.68 While controls performed
better when the image was presented centrally
compared with peripheral presentation, AMD patients
performed worse at all locations than controls and did
not perform better for central than peripheral
presentations.
In another experiment,69 participants were presented
with a view of a scene (the prime view) and asked to
change the viewpoint in a computer program represent-
ing the scene, until the viewpoint matched the prime
view. Controls (n=13) and AMD patients (n=19) had bias
towards ‘middle views’ of a scene; this was more pro-
nounced in AMD patients. Authors hypothesised that
disruption to central vision causes incorrect scene
perception.
Computer use
Six studies investigating the effect of AMD on computer
use were identiﬁed. These included a total of 57 partici-
pants with AMD. Four of these were case–control
studies, while two were case series.
AMD may result in difﬁculty using computers.70–75
Performance in a simple task involving identiﬁcation of
commonly used computer icons was signiﬁcantly asso-
ciated with worsening VA, contrast sensitivity (CS) and
colour vision defects in 18 people with AMD.73 Other
studies found that performance could also be affected
by features of the graphical user interface,70 71 74 75
although all but one73 of these studies investigated only
six or less people with AMD. Patients with dry AMD have
been shown to beneﬁt from auditory and haptic feed-
back when performing computer-based tasks.72
Other tasks
In a case–control study of 100 people with AMD (92
with nAMD), 48% were able to tell the time from a bold-
faced wall clock 1.5 m away, 70% correctly identiﬁed the
colour of four handkerchiefs coloured red, blue, tan
and grey, and 68% correctly identiﬁed four commonly
used household products when presented with well-
known brands of cereal, tomato ketchup, dish detergent
and milk.56 Differences between people with (n=10) and
without (n=10) AMD have been reported in a case–
control study investigating performance of reach-to-grasp
tasks.76 A further case–control study77 reported that
poor handwriting legibility in eight patients with
scotoma caused by AMD may be a result of difﬁculty
placing letters in the correct location due to inability to
view the writing area.
Patient-reported outcomes
Patient-reported visual function
Twenty-two studies investigating the effect of AMD on
patient-reported general visual function were identiﬁed.
These included a total of 10 877 participants with AMD.
Twenty of these were cross-sectional studies and two were
cohort studies.
The National Eye Institute Vision Function
Questionnaire (NEI-VFQ) is a widely used PROM in
AMD.23 Average scores are reported to be poorer in
people with AMD compared to those without16 78–84
and, unsurprisingly, worse in more severe disease.16 83–85
Results from studies using different tools are mostly
aligned with these ﬁndings.86–90 A prospective longitu-
dinal study investigating change in visual function in 671
women with AMD over a 5-year period found worse
NEI-VFQ scores in those with late AMD at the beginning
and end of the study compared to those progressing
from early to late AMD.91 Two large-scale cross-sectional
studies investigating 2194 and 1052 people with AMD
found no association84 and weak association92 with early
AMD, respectively, although a smaller study (n=106)
using a different PROM did ﬁnd impaired visual func-
tion in those with mild AMD.88 Best and worst eye VA
were found to contribute independently to NEI-VFQ
scores.1 93 NEI-VFQ scores were worse in individuals with
binocular compared to monocular visual loss from
AMD,94 95 although 54 patients with blindness in one
eye reported greater emotional distress than 54 with bin-
ocular blindness, perhaps due to uncertainty regarding
future disease progression.96 Interestingly, patients with
high response on a neuroticism scale reported worse
visual function than those with average response, regard-
less of VA.97
Mobility
Seven studies investigating the effect of AMD on patient-
reported mobility were identiﬁed. These included a total
of 655 participants with AMD. Four of these were cross-
sectional, two were cohort studies and one was a longitu-
dinal study.
Two separate retrospective studies have reported lower
rates of motor vehicle collision among people with AMD
compared to matched controls.46 98 These and other
studies concluded that AMD patients self-regulate by
changing driving habits, for example, avoiding driving at
night, in unfamiliar areas or over long distances.99 100
Higher self-reported fall rates have been reported
among AMD patients compared with those without.78–80
Among AMD patients, reduced CS and VA have been
associated with more self-reported falls (using
diaries).101 Older women with AMD have been reported
to have almost twice the risk of injurious falls (self-
reported) than those without.102 AMD has been asso-
ciated with fear of falling,103 and another PROM-based
cross-sectional study concluded that limited life space
and activities due to fear of falling seem to mediate the
relationship between eye disease and depression.104
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Utility values
Eight cross-sectional studies investigating the effect of
AMD on utility values were identiﬁed. These included a
total of 1768 participants with AMD.
Utility values, a type of PROM, give quantitative
expressions of preference for given health states23 and
can be assessed using different methods. For example,
standard gamble ascertains risk people would be willing
to take in order not to have a certain health condition
and the time trade off hypothetically assesses life years
sacriﬁced in order to avoid the condition. Scores are
normally presented on a scale between 0 and 1; higher
scores indicate better health or less willing to take risks
to avoid a condition. Average values for AMD range
from 0.60 to 0.81;105–107 patients with worse vision loss
from AMD score lower than those with mild loss.105 A
different utility value scale yielded mean preference
values for nAMD patients of 0.62 to 0.64.108 Utility
values allow comparisons between different health con-
ditions. Values for AMD are comparable with asymptom-
atic HIV (0.69), mild osteoarthritis of the hip (0.69),
mild and moderate angina (0.88 and 0.83), mild and
moderate myocardial infarction (0.91 and 0.80) and dia-
betes mellitus (0.88).109 Values reported for other eye
diseases include glaucoma (0.64 to 1.0) and diabetic ret-
inopathy (0.59 to 0.94).110 One cross-sectional study111
compared utility values between AMD and diabetic retin-
opathy and found comparable values for equivalent
levels of VA loss in each disease. Another cross-sectional
study112 found CS to be a good predictor of utility values
in 209 AMD patients.
Utility values are often established from members of
the public who are given descriptions of the health con-
dition being assessed; these tend to yield higher values
than those from people with AMD.113 This is supported
by results of other studies114 115 using time trade off
scores which showed utility values were consistently over-
estimated by the public, non-ophthalmic and even
ophthalmologists when compared to ratings by AMD
patients themselves.114 115 It may be impossible to appre-
ciate the consequences of vision loss without having
experienced them.114
Depression
Fourteen studies investigating the effect of AMD on
depression were identiﬁed. These included a total of
1880 participants with AMD. Eight of these were cross-
sectional, two were cohort studies, one was longitudinal
and one was a case report.
Associations between levels of depression and AMD
have been reported in the literature.104 Estimated preva-
lence rates for depression range from 11% to 44%
among AMD patients,116–119 the highest of these
ﬁgures is two to three times the rate found for elderly
controls. In contrast, one cross-sectional study120 found
no association between AMD and depression.
Differences between results may arise from different
tools used to assess depression in these studies and
different recruitment methods (clinic-based vs popula-
tion/community-based sample). Selective mortality and
limiting eligibility criteria have also been suggested as
reasons for not ﬁnding an association in some studies.120
Depression in AMD has been reported to be strongly
correlated with increasing VA loss121 and is predicted by
neurotic personality.122 In other studies depressive symp-
toms, even if minimal, were associated with loss of visual
function regardless of VA level.122–127 AMD patients
(n=144) who reported poor adaptation to vision loss,
especially with respect to acceptance of and compensa-
tion for vision loss, reported more depressive symptoms
than those who adapted better.128 One case report high-
lights risk of suicide because of AMD-related vision
loss;129 eye-care providers should be trained to identify
patients at risk of suicidality.
Adaptation
Fourteen studies investigating adaptation to AMD were
identiﬁed. These included a total of 1122 participants
with AMD. Two of these were case–control, one was a
cohort study, four were longitudinal and three were
cross-sectional.
Studies have investigated adaptation to AMD based on
Heckhausen and Schulz life-span theory of
control.130 131 Usage of internal resources (such as time
and effort) was positively associated with ability to carry
out activities of daily living, and external resource
ﬁnding (such as using low vision services and aids) and
increase of motivational commitment were positively
associated with positive emotion.131 132 External
resource ﬁnding increased shortly after diagnosis,
perhaps as patients initially sought advice and
support.133 Internal resource usage and motivational
input have been found to decrease over time in AMD
patients, while external resource ﬁnding and replace-
ment of desired goals partially increased over this
time.134 External resource ﬁnding135 and replacement
of desired goals133 increased as patients lost ability to
carry out activities of daily living. Variations in coping
strategies, along with cognitive ability, have been
reported to inﬂuence self-report of visual function.136
One longitudinal study137 found decline in positive
mood over the ﬁrst 2 years following diagnosis, followed
by an increase between the third and ﬁfth years, with
some subsequent stability. AMD patients were found to
have poorer life satisfaction, greater stress,138 more emo-
tional problems, greater social dysfunction139 and
impaired activities of daily living over a 5-year period140
than those without.
Activities of daily living
Nine studies investigating the effect of AMD on activities
of daily living were identiﬁed. These included a total of
1279 participants with AMD. Seven of these were cross-
sectional, one was a case series and one was a case
report.
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Studies21 141 report that 39–45% of AMD patients
require help with at least one activity of daily living.
These studies and others78–80 suggest that between twice
and eight times as many AMD patients require assistance
with activities of daily living compared with those
without. Severity of AMD is associated with these difﬁcul-
ties,18 which are unlikely to be experienced if visual
function is unaffected,142 although night driving difﬁcul-
ties related to impaired scotopic sensitivity may occur
while VA remains relatively good.143 Activities commonly
affected include meal preparation, travelling, cleaning,
grooming, shopping, going out, navigating steps and
pavement curbs, noticing objects, hobbies, watching TV,
reading, driving (especially night driving) and using low
vision devices.18 21 88 143–145 In addition, ability to carry
out activities requiring visual resolution, such as reading,
can distinguish those who are capable of self-care only
with those who are able to care for themselves and
others. Likewise, ability to carry out household chores,
such as preparing food, can distinguish those who are
capable of self-care and those who are not.146
A case study147 of a patient with bilateral ring scot-
omas from AMD reported difﬁculties in ‘several activities
of daily living’, in particular driving and following the
ball when playing golf. The patient was reported to ﬁnd
compensatory scanning eye movements a useful way of
keeping desired areas in focus.
Qualitative data collection methods
Eleven studies using interviews, focus groups and diaries
to assess how AMD affects visual disability or QoL were
identiﬁed.148–158 Their aims included illustrating ‘living
with AMD’ and elucidating challenges caused by the
condition.148–155 Others investigated factors associated
with successful adaptation to AMD.156–158 The detailed
results of these studies will be the subject of a subse-
quent report.
Trends
Our systematic review discovered that the literature
representing the effects of AMD on QoL can be split
into four categories: wet AMD only; dry AMD only; both
types investigated with a breakdown and both types
investigated but without a breakdown or type not
reported. We show that the number of QoL and visual
ability papers published in these categories is increasing
over time in ﬁgure 3 (before 1985 no studies had been
published on the subject). This increase may simply be
attributed to the increasing number of papers and jour-
nals published. Nevertheless, these studies make up a
minute proportion of the body of literature on AMD as
a whole; a PubMed search for articles with ‘age-related
macular degeneration’ in their title published between
2010 and 2014 yields 2458 results, while only 47 papers
(<2%) published in this time were included in this sys-
tematic review.
DISCUSSION
Our review is timely. Although smaller scale systematic
reviews have been published in this ﬁeld,24–28 the most
recent large-scale systematic reviews were published
about 10 years ago.22 23 A more recent, non-systematic
review published in 2013159 cited only 30 papers. Over
half of the papers included in our study were published
since these other large-scale systematic reviews were
conducted.
Poku et al24 systematically reviewed utility values in
patients with diabetic retinopathy, diabetic macular
oedema and AMD in 2013 and concluded that accord-
ing to the existing literature, AMD and diabetic retinop-
athy impact negatively on QoL, with most current
research categorising by VA in patients’ better-seeing
eye. Tosh et al25 also conducted a systematic review of
preference-based measures of QoL in visual disorders in
2012 with similar results. Pinquart et al26 conducted a
meta-analysis comparing psychological well-being in
people with and without visual impairment. Results
suggest that psychological well-being may be affected by
having visual impairment, and in particular that those
with AMD are more at risk for reduced psychological
well-being than those with other causes of visual
Figure 3 Frequency of
published papers over time
grouped by AMD type reported.
AMD, age-related macular
degeneration.
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impairment. Depression and anxiety among those with
AMD was systematically reviewed by Dawson et al27 in
2014. Depression was found to be more prevalent
among those with AMD than those without.
Furthermore, worse disease severity was associated with
increased depressive symptoms. However, similar to the
results of this systematic review, wide variability was
found, perhaps due to differences in sample size and
tools used in included studies. Their results suggest no
relationship between AMD and anxiety. Qualitative
studies concerned with the experience of AMD were sys-
tematically reviewed in 2012.28 Emerging themes
centred on functional limitations, adaptation and inde-
pendence, feelings about the future, interaction with
health services, social engagement, disclosure and emo-
tional impacts.
Our review is the ﬁrst to integrate PROMs and
performance-based studies assessing QoL and everyday
visual function in AMD. The evidence presented in this
study supports previous reviews’ conclusions that AMD
impacts negatively on people’s lives. More is now under-
stood about some of these areas of impact, for example,
the relationship between AMD and falls,53 54 78–80 101–104
and scene perception.61–69 AMD negatively affects tasks
including mobility, face recognition, perception of
scenes, computer use, meal preparation, shopping,
cleaning, watching TV, reading, driving and, in some
cases, self-care. A large number of studies have high-
lighted the difﬁculties people with AMD may have with
mobility, particularly in dim lighting.48–51 Large-scale
studies have reported invariably that many people with
AMD self-report poor visual function; this worsens with
AMD severity.16 81 83 84 86 87 90–93 95 97 There is limited
evidence surrounding the issues people with AMD may
have with using computers, due to the small sample sizes
of the majority of studies identiﬁed.70–72 75
A number of domains within people’s lives are
affected by AMD: social, emotional and physical. Our
systematic review highlights the need for eye-care provi-
ders to be aware of this research evidence, and to be
able to manage these patients, whether it be referral for
low vision rehabilitation or help from social or counsel-
ling services. Previous research114 115 has shown that
people without AMD, including eye-care providers, con-
sistently underestimate the effect of the condition and
it would be interesting to discover whether public per-
ceptions are different now, with the advent of news-
worthy potential new treatments. For example, a
Google search for news articles about ‘age-related
macular degeneration treatment’ published in 2004
generates three web pages of results, while a search for
articles on the same topic published in 2014 generates
76 web pages.
We have also identiﬁed interesting trends in the publi-
cation of studies in this ﬁeld (ﬁgure 3). There were no
publications on QoL and visual disability in nAMD
before 2000, and then there was a sudden increase; this
is noteworthy and may be explained by the development
of new treatments for nAMD around this time.160 161
These are likely to have resulted in increased interest in
investigating QoL and functional impacts in order to
assess clinical and cost-effectiveness outcomes of these
new treatments.106 Few papers report the type of AMD
investigated (41%, n=51)—worrying given the functional
differences between the disease types, along with their dif-
fering time courses and treatments.27 It is, however,
encouraging that more papers that include both types are
now providing a breakdown between the two. Five and 25
papers focus solely on dry AMD and wet AMD respect-
ively. This is disproportionate, given that dry AMD com-
prises ∼90% of diagnosed AMD cases.162 In addition, 74%
of included studies (n=93) do not report disease duration.
As psychological and functional effects can change over
the time course of the disease, this should be an import-
ant feature on which to report and comment.
Our results are supported by other studies,27 28 which
discuss the lack of discrimination between wet and dry
AMD in research. We spotlight this observation to be
true in the majority of papers published in this ﬁeld
(ﬁgure 3). Critically, results from studies that did dis-
criminate between the two indicate that QoL and visual
function are affected in unique ways depending on
disease type. For example, one study126 reported more
nAMD patients than dry AMD patients suffering from
depression. Another148 discussed the optimism that
nAMD patients may feel receiving treatment and empha-
sised the sense of loss that those with dry AMD may
suffer from due to lack of treatment. We think these
ﬁndings are interesting, and more research addressing
these differences is likely required.28
This study has limitations. First, only papers published
in peer-reviewed journals were included. This is likely to
have inﬂuenced the results found due to submission bias
and/or publication bias. Second, the nature of this
review meant that randomised control trials were
excluded. Third, due to lack of translation resources,
non-English language papers were excluded. Fourth, the
impact of AMD on reading was not considered in this
study because we felt this is a topic that is already very
well reported on. For example, previous extensive reviews
report reduced reading performance in AMD29 30 and
subsequently reading is one of the most common valued
activities to be lost as a result of AMD.23 It is also worth
noting that research in this ﬁeld is not straightforward.
For example, disentangling the effects of age alone from
age-related eye disease is a challenge that often requires
well-deﬁned age-matched or age-related controls.
Moreover, isolating the effect of AMD when elderly
people have comorbidities is also a challenge. Still, using
MMAT for our appraisal revealed most studies to have
high levels of methodological quality.
CONCLUSIONS
Performance-based measures and PROMs have shown
AMD to negatively affect QoL and visual disability; it
Taylor DJ, et al. BMJ Open 2016;6:e011504. doi:10.1136/bmjopen-2016-011504 9
Open Access
 o
n
 30 August 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-011504 on 2 December 2016. Downloaded from 
affects many activities of daily living including, for
example, mobility, driving, face recognition, scene per-
ception and computer use. From earlier reviews, we
know AMD also impacts critically on reading. Emotional
impact can be severe. These impacts can differ over the
time course of the disease, perhaps due to adaptation,
and this should be acknowledged and investigated in
future research. Future research in this ﬁeld should also
focus on delivering some of this research knowledge
into the assessment of patients in clinical management
and clinical trials. In other words, successful clinical
management of AMD should not simply be about
changes on a letter chart (eg, VA or CS) but must
equate to correct decisions about intensifying treatment
when patients are at risk of developing ‘visual disability’.
Furthermore, our review highlights a requirement to dif-
ferentiate between types of AMD, especially as new
disease-type speciﬁc treatments emerge for them.
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